Pernix Therapeutics Holdings Inc (NASDAQ:PTX) announced today that it has been added to the Russell Microcap® index following the annual reconstitution, which took effect after the US market closed on Friday, June 23rd.
“We are pleased to be included in the Russell Microcap Index,” said John Sedor, Chairman and Chief Executive Officer of Pernix Therapeutics. “The Russell US Indexes are some of the leading US equity benchmarks for institutional investors. We believe inclusion in the Russell Microcap Index should increase our visibility in the financial marketplace and broaden our shareholder base since Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies.”
Shares of Pernix Therapeutics closed today at $4.14, down $0.13 or -3.04%. PTX has a 1-year high of $10.40 and a 1-year low of $1.83. The stock’s 50-day moving average is $4.58 and its 200-day moving average is $3.62.
Pernix Therapeutics Holdings, Inc. engages in the research, development, and manufacture of biopharmaceutical products. It focuses on therapeutics for diseases on central nervous system, neurology, pain, and psychiatry. Its products include treatment of migraine pain and inflammation, insomnia, and depressive disorder. The firm distributes its products under the following brands: Treximet, Silenor, Zohydro ER with BeadTek, and Khedezla.